3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Prostatic Neoplasms
195
Prostatic Neoplasms, Castration-Resistant
20
Neoplasm Metastasis
20
Metastatic Castration Resistant Prostate Cancer
10
Prostate Cancer Metastatic
7
Metastatic Castration-Resistant Prostate Cancer
7
Metastatic Castration-resistant Prostate Cancer
6
Neoplasms
5
Castration-resistant Prostate Cancer
5
Breast Neoplasms
5
Pancreatic Neoplasms
4
Melanoma
4
Colorectal Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Bulbo-Spinal Atrophy, X-Linked
4
Adenocarcinoma
4
Urinary Bladder Neoplasms
3
Prostate Adenocarcinoma
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Carcinoma, Renal Cell
3
Carcinoma, Hepatocellular
3
Uterine Cervical Neoplasms
2
Triple Negative Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Prostatic Diseases
2
Ovarian Neoplasms
2
Non-metastatic Castration-resistant Prostate Cancer
2
Metastatic Hormone-sensitive Prostate Cancer
2
Metastatic Hormone Sensitive Prostate Cancer
2
Interventions
Cyclophosphamide
7
pembrolizumab
6
fludarabine
6
aldesleukin
4
fludarabine phosphate
2
entinostat
2
Trastuzumab
2
Radiotherapy
2
Psychiatric Rehabilitation
2
Nivolumab
2
Interleukin-2
2
Interleukin-12 Subunit p35
2
Early Intervention, Educational
2
Adoptive Transfer
2
trastuzumab deruxtecan
1
tislelizumab
1
tipifarnib
1
spartalizumab
1
rocakinogene sifuplasmid
1
oncogene protein E7, Human papillomavirus type 16
1
enzalutamide
1
durvalumab
1
cemiplimab
1
bintrafusp alfa protein, human
1
atezolizumab
1
alovudine
1
abiraterone
1
Vorinostat
1
Vaccines, Synthetic
1
VGX-3100
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Anus Neoplasms
×
enzalutamide
×
Genitourinary
×
Clear all
NCT05551117
2026-02-09
Tamarack
MacroGenics
Phase 2
Terminated
192 enrolled
20 charts